Improvement in insulin sensitivity and a normalization of ALT levels that were four times greater than the placebo group; a significant 30% decrease in hepatic steatosis was observed; there was no significant histological improvement in the rosiglitazone group compared to the placebo group. The gene discussed is GPT; the disease is fatty liver disease.